Shenzhen Neptunus Interlong Bio-technique Company Limited, together with its subsidiaries, engages in the research and development, manufacturing, and selling of medicines and medical devices in the People's Republic of China. It operates through two segments, Manufacturing and Selling of medicines and medical devices; and Sales and Distribution of medicines and healthcare products, and medical devices. The company offers medicines for various therapeutic areas, including oncology, cardiovascular system, respiratory system, digestive system, and mental diseases. It is also involved in the purchase, sale, and distribution of medicines and healthcare food products; and research and development of biological technology business. Shenzhen Neptunus Interlong Bio-technique Company Limited was incorporated in 2002 and is based in Quarry Bay, Hong Kong. Shenzhen Neptunus Interlong Bio-technique Company Limited operates as a subsidiary of Shenzhen Neptunus Bio-engineering Company Limited.
Research context
Shenzhen Neptunus Interlong Bio-technique Company Limited appears in PyInvesting’s Hong Kong Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- HKD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Shenzhen Neptunus Interlong Bio-technique Company Limited is currently in a long term downtrend where the price is trading 17.2% below its 200 day moving average.
From a valuation standpoint, the stock is 99.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.3.
Shenzhen Neptunus Interlong Bio-technique Company Limited's total revenue sank by 14.3% to $272M since the same quarter in the previous year.
Its net income has dropped by 65.6% to $8M since the same quarter in the previous year.
Finally, its free cash flow grew by 163.5% to $71M since the same quarter in the previous year.
Based on the above factors, Shenzhen Neptunus Interlong Bio-technique Company Limited gets an overall score of 2/5.